CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets of 4.40% for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2025 was 4.40%, a 25.71% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2024 was 3.50%, a 10.26% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2023 was 3.90%, a 62.50% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2022 was 2.40%, a 4.00% decline from fiscal 2021.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 12 month | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 12 month as first filed |
|---|---|---|
| 2025-12-27 | 4.40% 10-K · filed 2026-02-18 | |
| 2024-12-28 | 3.50% 10-K · filed 2026-02-18 | |
| 2023-12-30 | 3.90% 10-K · filed 2026-02-18 | |
| 2022-12-31 | 2.40% 10-K · filed 2025-02-19 | |
| 2021-12-25 | 2.50% 10-K · filed 2024-02-14 | |
| 2020-12-26 | 3.40% 10-K · filed 2023-02-22 | 3.35% 10-K · filed 2021-02-17 |
| 2019-12-28 | 4.30% 10-K · filed 2022-02-16 | 4.28% 10-K · filed 2020-02-11 |
| 2018-12-29 | 5.18% 10-K · filed 2021-02-17 | |
| 2017-12-30 | 5.41% 10-K · filed 2020-02-11 | |
| 2016-12-31 | 5.83% 10-K · filed 2019-02-13 | |
| 2015-12-26 | 6.24% 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |